{"ticker": {"uuid": "67d0d4ce-eac4-455a-9a3b-418a5a493b16", "symbol": "ELIC", "name": "Elicera Therapeutics AB (publ)", "exchange": "STO", "country": "SE", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "BioVal\u2122 analysis: Elicera Therapeutics' ELC-301 valued at SEK 631M", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPcUFJenVoMVNZMmZzUG9wRE1Rdy1kT2dqc2pLVlJQaS1PcXRfSGZYYWpwX0pka0M1UGVmbmFXQmk0blNTMmdTUXhtZm9uYTB6Mk50ZEgzdzVOa3B3dzQ2RFJ3ajhTYVdMeVM0RmlTNW5Na2pJRTRHRHV6ZmFrWk9uZFlsLXhNSUxJWTFqdmFqMG5iLS1IRGNPZFhZMA?oc=5", "source_name": "Biostock", "published_at": "2026-07-02T06:01:04+00:00", "published_display": "02 Jul 2026 06:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Hopeful That Elicera Therapeutics (STO:ELIC) Will Use Its Cash Wisely", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "BioVal\u2122 analysis: Elicera Therapeutics' ELC-301 valued at SEK 631M", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPcUFJenVoMVNZMmZzUG9wRE1Rdy1kT2dqc2pLVlJQaS1PcXRfSGZYYWpwX0pka0M1UGVmbmFXQmk0blNTMmdTUXhtZm9uYTB6Mk50ZEgzdzVOa3B3dzQ2RFJ3ajhTYVdMeVM0RmlTNW5Na2pJRTRHRHV6ZmFrWk9uZFlsLXhNSUxJWTFqdmFqMG5iLS1IRGNPZFhZMA?oc=5", "source_name": "Biostock", "published_at": "2026-07-02T06:01:04+00:00", "published_display": "02 Jul 2026 06:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Hopeful That Elicera Therapeutics (STO:ELIC) Will Use Its Cash Wisely", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 77, "total_relevant": 2, "sentiment_summary": {"positive": 0, "negative": 0, "neutral": 2, "score": 50, "total": 2, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 58, "events": [{"event": "general", "label": "Market update", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 0, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 2.77, "latest_week": "2026-07-10", "one_week_move": -5.6, "four_week_move": 3.9, "twelve_week_move": -47.9, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.94612, "market_dynamics_buy_signal": false, "relative_strength": -52.017353, "fair_value_gap": -22.8, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 52.5874, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-5.6% over one week, +3.9% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 50, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Biostock", "count": 1}, {"label": "simplywall.st", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 2}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "58/100 classification confidence."}, {"label": "Company focus", "value": "2", "tone": "neutral", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-5.6% over one week, +3.9% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "BioVal\u2122 analysis: Elicera Therapeutics' ELC-301 valued at SEK 631M"}], "updated_at": "2026-07-18T03:40:35.959691+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}